1. Home
  2. ANIX vs ONCY Comparison

ANIX vs ONCY Comparison

Compare ANIX & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

N/A

Current Price

$2.76

Market Cap

114.0M

Sector

Health Care

ML Signal

N/A

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

N/A

Current Price

$0.64

Market Cap

109.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANIX
ONCY
Founded
1982
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.0M
109.1M
IPO Year
2013
2002

Fundamental Metrics

Financial Performance
Metric
ANIX
ONCY
Price
$2.76
$0.64
Analyst Decision
Strong Buy
Buy
Analyst Count
4
6
Target Price
★ $9.75
$4.15
AVG Volume (30 Days)
333.6K
★ 975.4K
Earning Date
09-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 12.82
N/A
EPS
N/A
★ N/A
Revenue
★ $210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$0.64
52 Week High
$5.46
$1.42

Technical Indicators

Market Signals
Indicator
ANIX
ONCY
Relative Strength Index (RSI) 48.33 30.39
Support Level $2.82 $0.64
Resistance Level $3.03 $0.89
Average True Range (ATR) 0.13 0.04
MACD 0.04 -0.01
Stochastic Oscillator 93.51 8.69

Price Performance

Historical Comparison
ANIX
ONCY

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Share on Social Networks: